

SDC 1. Oncologic treatment

	Previously augmented (Group A) (n=20)	Reconstructed non-augmented (Group B) (n=222)	Non-reconstructed and non-augmented (Group C) (n=228)	<i>p</i> -value
Neoadjuvant treatment*				
Yes	5 (25.0%)	40 (18.0%)	48 (21.1%)	0.60
Adjuvant chemotherapy*				
Yes	7 (35.0%)	101 (45.5%)	106 (46.5%)	0.61
Adjuvant hormone therapy*				
Yes	14 (70.0%)	162 (73.0%)	172 (75.4%)	0.77
Adjuvant radiation therapy*				
Yes	5 (25.0%)	50 (22.5%)	69 (30.3%)	0.18
Time to surgery (days)**	75.7 (70.6)	76.2 (117.9)	60.6 (74.3)	0.23
Type of surgery*				
Bilateral TM	10 (50.0%)	140 (63.1%)	89 (39.0%)	
Bilateral MRM	0 (0.0%)	0 (0.0%)	2 (0.9%)	
Bilateral NSM	1 (5.0%)	20 (9%)	1 (0.4%)	
Unilateral NSM	1 (5.0%)	3 (1.4%)	0 (0.0%)	
Unilateral TM	4 (20.0%)	37 (16.7%)	78 (34.2%)	
Unilateral MRM	2 (10.0%)	6 (2.7%)	34 (14.9%)	
Unilateral RM	1 (5.0%)	1 (0.5%)	0 (0.0%)	

MRM with contralateral TM	1 (5.0%)	15 (6.8%)	22 (9.6%)	<0.001
Disease status at last follow-up*				
No evidence of disease	20 (100.0%)	219 (98.6%)	212 (93.0%)	
Ongoing treatment	0 (0.0%)	0 (0.0%)	5 (2.2%)	
Recurrence	0 (0.0%)	3 (1.4%)	11 (4.8%)	0.03

Notes. TM= Total mastectomy; MRM= Modified radical mastectomy; NSM= Nipple-sparing mastectomy; RM= Radical mastectomy.

* Denotes outcomes reported as total number (percentage).

** Denotes outcomes reported as average (standard deviation).

Bold indicates $p < 0.05$, statistically significant.